DEF: Sight Sciences 2026 Annual Meeting Proxy Statement

Sight Sciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 4, 2026, at 9:00 a.m. Pacific Time via virtual webcast.
• Stockholders of record as of April 8, 2026, are entitled to vote.
• Proposal 1: Election of Gerhard Burbach and Staffan Encrantz as Class II Directors until the 2029 Annual Meeting.
• Proposal 2: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The company reported 2025 revenue of $77.4 million, a 3% decrease from $79.9 million in 2024.
• Adjusted operating expenses for 2025 were $87.8 million, a 13% decrease from $101.3 million in 2024, following a restructuring plan that reduced headcount by approximately 20%.
• The company introduced performance-based restricted stock units (PRSUs) for the CEO, COO, and CFO in the 2026 equity grant cycle.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious filing, reflecting a company in a defensive posture due to revenue shortfalls and reimbursement headwinds, though management is taking active steps to restructure and align incentives with performance.

Positives

• Achieved maximum payout (150% of target) for adjusted operating expense management, reducing expenses by 13% year-over-year.
• Achieved maximum payout (150% of target) for TearCare market access regarding average payment rates for CPT code 0563T.
• Successfully launched the OMNI Edge product.
• Maintained a disciplined approach to equity burn rate, keeping it at or below 6% of outstanding shares.
• Successfully implemented a restructuring plan in 2025 to improve cost efficiencies and align the operating structure for long-term growth.

Negatives

• Total revenue of $77.4 million for 2025 was below the minimum threshold ($82.0 million) for the revenue-based incentive payout.
• Interventional Dry Eye revenue decreased by 59% ($2.3 million) compared to the prior year.
• Did not achieve the 2025 commercial objective regarding the launch of a specific next-generation OMNI product.
• Failed to meet the minimum threshold for the 'kicker' incentive related to achieving three or more coverage policies/fee schedules.
• Experienced significant market headwinds due to the 'Multiple MIGS Exclusion' in Medicare coverage determinations.

Risks

• Uncertainty regarding Medicare reimbursement and coverage determinations (LCDs) for MIGS procedures.
• Impact of the 'Multiple MIGS Exclusion' on device usage volumes and revenue.
• Intense competitive pressures in the medical device market.
• Potential for future revenue growth to be lower than anticipated if Standalone Market development efforts do not gain sufficient traction.
• Risks associated with the reliance on third-party payors for equitable reimbursement of the TearCare procedure.

Future Outlook

The company expects most Interventional Glaucoma revenue growth in 2026 to come from increased combination cataract procedures. It plans to continue leveraging initial fee schedules for TearCare to educate other payors and drive adoption, while maintaining operating discipline to preserve cash for priority initiatives.

Management Comments

• The Board believes that separation of the positions of Chairperson and Chief Executive Officer reinforces the independence of the Board from management.
• The company is passionate about improving patients lives by helping them to preserve their sight.
• The committee believes that performance-based equity awards will play an important role in the equity compensation structure moving forward.

Industry Context

StockSavvy.ai notes that Sight Sciences is navigating a challenging reimbursement environment common to the MIGS (Minimally Invasive Glaucoma Surgery) sector, where Medicare Administrative Contractor (MAC) coverage policies significantly impact device utilization and revenue growth. The company's pivot toward performance-based equity and cost restructuring reflects broader industry trends of prioritizing profitability and operational efficiency over aggressive growth in the current high-interest-rate and uncertain reimbursement climate.

Comparison to Industry Standards

• The company's peer group for 2026 includes 19 companies in the medical device and biotechnology industries, such as RxSight, CVRx, and Treace Medical Concepts.
• The company's executive compensation philosophy has shifted away from strict benchmarking to a more holistic assessment, aligning with evolving governance practices among small-cap medical technology firms.
• The use of PRSUs for executive compensation is increasingly becoming a standard practice among publicly traded medical device companies to align management incentives with specific revenue milestones.

Corporate Governance

Stakeholder Impact

• Shareholders: Impacted by revenue decline and restructuring; potential for long-term value creation through new performance-based equity incentives.
• Employees: Impacted by a 20% reduction in global workforce during 2025.
• Customers: Continued focus on providing interventional solutions for glaucoma and dry eye.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 4, 2026.
• Execute 2026 corporate objectives, including driving revenue growth and TearCare market access.
• Continue development of the OMNI standalone market and product pipeline.

Key Dates

Recommendation

The company is currently in a transition phase, managing significant reimbursement headwinds and internal restructuring. While the focus on operational discipline and performance-based compensation is positive, the revenue decline and delayed product launches suggest a 'hold' until there is clearer evidence of sustained revenue growth and successful market penetration for the TearCare system.

Keywords

Sight Sciences, SGHT, Proxy Statement, Annual Meeting, Medical Devices, Ophthalmology, MIGS, TearCare, Corporate Governance, Executive Compensation